Drugs / BIFIDOBACTERIUM SPP.
BIFIDOBACTERIUM SPP.
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07188909 | Sep 2025 → Mar 2026 overdue | acute graft versus host disease | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| — | NCT06287931 | Jan 2024 → Jun 2025 | gallstones | Shandong Linglong Yingcheng Hospital | Unknown | No outcome recorded |
| — | NCT06325605 | Mar → Oct 2022 | — | Zhen-Hong Hu | Completed | No outcome recorded |
| — | NCT03330184 | Oct 2015 → Apr 2018 | — | Xijing Hospital | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-11-25 | AB Biotics, SA | Results WCPGHAN 2024: Discover the compelling results of the first comparative clinical trial between AB-KOLICARE® and L. reuteri DSM17938 for infant colic ab-biotics.com ↗
Moreover, the response rates for both probiotic groups aligned with previously published results, reinforcing the reliability of the data. |
| 2023-05-16 | AB Biotics, SA | Results Explore our latest study at ESPGHAN 2023 revealing the intestinal barrier protection of our Bifidobacterium strain ab-biotics.com ↗ |
| 2022-05-03 | Prolacta Bioscience | Results Study published in the journal Cell Host & Microbe offers proof of concept that a human milk-based synbiotic could allow therapeutic manipulation of the gut microbiome prolacta.com ↗
In the publication “Dosing a Synbiotic of Human Milk Oligosaccharides and B. infantis Leads to Reversible Engraftment in Healthy Adult Microbiomes Without Antibiotics,” scientists report that in healthy adult subjects, simultaneous ingestion of a combination of human milk-derived HMOs and B. infantis results in high-level, controllable, HMO-dependent engraftment of B. infantis . |
| 2021-09-09 | AB Biotics, SA | Results New outstanding AB-KOLICARE™ clinical data published in Frontiers ab-biotics.com ↗
It found that supplementation with AB-KOLICARE™ for 21 days resulted in shorter crying and/or fussing time and less episodes of crying and/or fussing compared to the placebo group. |
| 2016-06-28 | Yakult Honsha Co., LTD | Results 乳児ビフィズス菌の共生機構を分子レベルで解明 yakult.co.jp ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-25 | AB Biotics, SA | WCPGHAN 2024: Discover the compelling results of the first comparative clinical trial between AB-KOLICARE® and L. reuteri DSM17938 for infant colic ab-biotics.com ↗ |
| 2023-05-16 | AB Biotics, SA | Explore our latest study at ESPGHAN 2023 revealing the intestinal barrier protection of our Bifidobacterium strain ab-biotics.com ↗ |
| 2022-05-03 | Prolacta Bioscience | Study published in the journal Cell Host & Microbe offers proof of concept that a human milk-based synbiotic could allow therapeutic manipulation of the gut microbiome prolacta.com ↗ |
| 2021-09-09 | AB Biotics, SA | New outstanding AB-KOLICARE™ clinical data published in Frontiers ab-biotics.com ↗ |
| 2021-03-15 | Pendulum Therapeutics | What is Bifidobacterium infantis? pendulumlife.com ↗ |
| 2016-06-28 | Yakult Honsha Co., LTD | 乳児ビフィズス菌の共生機構を分子レベルで解明 yakult.co.jp ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIFIDOBACTERIUM SPP. | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297912 ↗ |
| Known as | Bifidobacteria | “Bifidobacteria, 210 mg po tid x 6 months” NCT06287931 ↗ |
| Known as | Bifidobacterium | “Target isolation and culture of core beneficial bacteria (Lactobacillus and Bifidobacterium)” NCT07188909 ↗ |
| Known as | Bifidobacterium nos | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297912 ↗ |
| Modality | Other / unclassified | “Bifidobacterium, as a familiar probiotics” NCT03330184 ↗ |
| Route | Oral | “Bifidobacteria, 210 mg po tid x 6 months” NCT06287931 ↗ |